Second nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by Japanese Surveillance Committee from 2015 to 2016: antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus.

Adolescent Adult Anti-Bacterial Agents / pharmacology Cystitis / drug therapy Drug Resistance, Multiple, Bacterial Epidemiological Monitoring Escherichia coli / drug effects Female Humans Japan Klebsiella pneumoniae / drug effects Male Microbial Sensitivity Tests Middle Aged Staphylococcus saprophyticus / drug effects Young Adult beta-Lactamases / metabolism
Acute uncomplicated cystitis Resistance Surveillance Susceptibility

Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 09 01 2019
revised: 17 02 2019
accepted: 25 02 2019
pubmed: 25 3 2019
medline: 3 9 2019
entrez: 26 3 2019
Statut: ppublish

Résumé

The Japanese Surveillance Committee conducted a second nationwide surveillance of antimicrobial susceptibility patterns of uropathogens responsible for acute uncomplicated cystitis (AUC) in premenopausal patients aged 16-40 years old at 31 hospitals throughout Japan from March 2015 to February 2016. In this study, the susceptibility of causative bacteria (Escherichia coli, Klebsiella pneumoniae, Staphylococcus saprophyticus) for various antimicrobial agents was investigated by isolation and culturing of organisms obtained from urine samples. In total, 324 strains were isolated from 361 patients, including E. coli (n = 220, 67.9%), S. saprophyticus (n = 36, 11.1%), and K. pneumoniae (n = 7, 2.2%). The minimum inhibitory concentrations (MICs) of 20 antibacterial agents for these strains were determined according to the Clinical and Laboratory Standards Institute (CLSI) manual. At least 93% of the E. coli isolates showed susceptibility to fluoroquinolones and cephalosporins, whereas 100% of the S. saprophyticus isolates showed susceptibility to fluoroquinolones and aminoglycosides. The proportions of fluoroquinolone-resistant and extended-spectrum β-lactamase (ESBL)-producing E. coli strains were 6.4% (13/220) and 4.1% (9/220), respectively. The antimicrobial susceptibility of K. pneumoniae was retained during the surveillance period, while no multidrug-resistant strains were identified. In summary, antimicrobial susceptibility results of our second nationwide surveillance did not differ significantly from those of the first surveillance. Especially the numbers of fluoroquinolone-resistant and ESBL-producing E. coli strains were not increased in premenopausal patients with AUC in Japan.

Identifiants

DOI: 10.1016/j.jiac.2019.02.021 PMID: 30905628
pubmed: 30905628
pii: S1341-321X(19)30063-7
doi: 10.1016/j.jiac.2019.02.021
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

413-422

Informations de copyright

Copyright © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

Hiroshi Hayami (H)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Blood Purification Center, Kagoshima University Hospital, Kagoshima, Japan. Electronic address: bass@m.kufm.kagoshima-u.ac.jp.

Satoshi Takahashi (S)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.

Kiyohito Ishikawa (K)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, School of Medicine, Fujita Health University, Toyoake, Japan.

Mitsuru Yasuda (M)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Gifu University Hospital, Gifu, Japan.

Shingo Yamamoto (S)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Hyogo College of Medicine, Hyogo, Japan.

Koichiro Wada (K)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Kanao Kobayashi (K)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Chugoku Rosai Hospital, Hiroshima, Japan.

Ryoichi Hamasuna (R)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.

Shinichi Minamitani (S)

The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Daiichi Sankyo Co., Ltd, Japan.

Tetsuya Matsumoto (T)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.

Hiroshi Kiyota (H)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan.

Kazuhiro Tateda (K)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.

Junko Sato (J)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.

Hideaki Hanaki (H)

Infection Control Research Center, Kitasato University, Tokyo, Japan.

Naoya Masumori (N)

Department of Urology, Sapporo Medical University School of Medicine, Hokkaido, Japan.

Hiroyuki Nishiyama (H)

Department of Urology, University of Tsukuba, Ibaraki, Japan.

Jun Miyazaki (J)

Department of Urology, University of Tsukuba, Ibaraki, Japan.

Kiyohide Fujimoto (K)

Department of Urology, Nara Medical University, Nara, Japan.

Kazushi Tanaka (K)

Division of Urology, Department of Surgery Related Faculty of Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan.

Shinya Uehara (S)

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Akio Matsubara (A)

Department of Urology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.

Kenji Ito (K)

Ito Urology Clinic, Fukuoka, Japan.

Kenji Hayashi (K)

Tomakomai Urology and Cardiology Clinic, Hokkaido, Japan.

Yuichiro Kurimura (Y)

Tomakomai Urology and Cardiology Clinic, Hokkaido, Japan.

Shin Ito (S)

iClinic, Miyagi, Japan.

Toshimi Takeuchi (T)

Takeuchi Urology and Dermatology Clinic, Gifu, Japan.

Harunori Narita (H)

Narita Clinic, Aichi, Japan.

Masanobu Izumitani (M)

Izumitani Fureai Clinic, Aichi, Japan.

Hirofumi Nishimura (H)

Nishimura Urology Clinic, Fukuoka, Japan.

Motoshi Kawahara (M)

Kawahara Urology Clinic, Kagoshima, Japan.

Makoto Hara (M)

Department of Urology, Tsujinaka Hospital Kashiwanoha, Chiba, Japan.

Takahide Hosobe (T)

Hosobe Clinic, Tokyo, Japan.

Kenji Takashima (K)

Takashima Urology Clinic, Nara, Japan.

Hirofumi Chokyu (H)

Cyokyu Tenma Clinic, Hyogo, Japan.

Masaru Matsumura (M)

Matsumura Urology Clinic, Hyogo, Japan.

Hideari Ihara (H)

Ihara Clinic, Hyogo, Japan.

Satoshi Uno (S)

Hirajima Clinic, Okayama, Japan.

Koichi Monden (K)

Araki Urological Clinic, Okayama, Japan.

Toru Sumii (T)

Sumii Clinic, Hiroshima, Japan.

Shuichi Kawai (S)

Kawai Urology Clinic, Fukuoka, Japan.

Satoru Kariya (S)

Ootemachi Clinic, Kagoshima, Japan.

Takashi Sato (T)

Nissin Urological Clinic, Hokkaido, Japan.

Masaru Yoshioka (M)

Yoshioka Urology Clinic, Hyogo, Japan.

Hitoshi Kadena (H)

Kadena Urological Clinic, Hiroshima, Japan.

Shinji Matsushita (S)

Department of Urology, Kagoshima Prefectural Ohshima Hospital, Kagoshima, Japan.

Shohei Nishi (S)

Nishi Urology and Dermatology Clinic, Fukuoka, Japan.

Yukinari Hosokawa (Y)

Department of Urology, Tane General Hospital, Osaka, Japan.

Takeshi Shirane (T)

Shirane Urology Clinic, Hiroshima, Japan.

Mutsumasa Yoh (M)

Yoh Urology and Dermatology Clinic, Aichi, Japan.

Syuji Watanabe (S)

Department of Urology, Saiseikai Chuwa Hospital, Nara, Japan.

Shinichi Makinose (S)

Makinose Urological Clinic, Kagoshima, Japan.

Tetsuji Uemura (T)

Remedy Kitakyushu Nephro Clinic, Fukuoka, Japan.

Hirokazu Goto (H)

Department of Urology, Fuji City Genaral Hospital, Shizuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies de la vessie › Cystite › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Multirésistance bactérienne aux médicaments › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Surveillance épidémiologique › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Escherichia › Escherichia coli › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Régions géographiques › Iles › Japon › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Klebsiella › Klebsiella pneumoniae › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus saprophyticus › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Second nationwide surveillance of bacterial...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Amidohydrolases › bêta-Lactamases › Second nationwide surveillance of bacterial...